Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06257472
Other study ID # VR Study
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date February 2025

Study information

Verified date March 2024
Source The Cleveland Clinic
Contact Anthony Lembo, MD
Phone (216) 554-3531
Email lemboa2@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the investigators conduct a remote, eight-week, two-arm, randomized controlled trial that assesses the benefits, primarily measured through the irritable bowel syndrome (IBS)-targeted HRQOL (health-related quality of life), of an immersive, disease-targeted virtual reality program compared to a non-immersive virtual reality program for patients with IBS.


Description:

In this study, the investigators will conduct a decentralized, remote, eight-week, two-arm, randomized controlled trial of SynerGI, a disease-targeted, brain-gut directed, immersive VR program for people with IBS, versus sham VR delivered in a VR headset. Eligible participants will be assigned to a study arm using a 1:1 random number generator and will be blinded to allocation. Data analysts will also be blinded to allocation; only pre-specified staff who are uninvolved with data analyses will be unblinded for purposes of study administration (e.g., sending allocation-specific study materials). After completion of the treatment, participants will be invited to participate in an optional 30-minute semi-structured interview to better understand their experiences of VR treatment. Qualitative interviews will be audio-recorded and transcribed. The primary aim of this study will be to assess the benefits of disease-targeted VR compared to sham VR on clinically relevant outcomes. The second aim will seek to determine patient-level predictors of treatment response to active VR therapy. The third aim will seek to understand patient experiences of VR to better inform the design of VR treatments for digestive diseases in the future.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - English-speaking - 18 years or older - Meet Rome IV criteria, as diagnosed either by a licensed physician or via self-report using the Rome IBS questionnaire, for IBS for any type: IBS-C (IBS with constipation), IBS-D (IBS with diarrhea), and IBS-M (mixed-type IBS) Exclusion Criteria: - Individuals with a comorbid disorder that may confound the diagnosis of IBS, including: - celiac disease - inflammatory bowel disease - autoimmune disorders that affect the GI system - history of bowel resection - HIV/AIDS ( human immunodeficiency virus/acquired immunodeficiency syndrome) - diabetes with HgA1c>7.0 - neuroendocrine tumors - microscopic colitis - lactase deficiency - eosinophilic bowel disease - acute intermittent porphyria - any other condition that a licensed physician believes can mimic IBS symptoms and undermine diagnostic certitude - Patients using regular doses of opioid medications will also be excluded given the often-severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia - No WiFi at home - Any history of seizure - Ongoing treatment for a GI cancer - Major audiovisual impairment (complete blindness, deafness) - Inability to understand English at 6th grade level - Any events planned over the 8 weeks of the study that could end your ability to participate in the study, such as a medical procedure, vacation, or change in residence (Note: the study team can always delay enrollment)

Study Design


Intervention

Device:
Virtual Reality Headset
Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.

Locations

Country Name City State
United States Cleveland Clinic Main Campus Cleveland Ohio
United States Cedars-Sinai Medical Center Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Anthony Lembo Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary IBS-targeted HRQOL (health-related quality of life) The primary outcome will be an increase in IBS-QOL (quality of life) scores between baseline and week 8 for those on the study arm. Each question is positively scored 1-5, and the sum is normalized into a 0-100 score, with 100 being the highest reported quality of life and 0 being the lowest. Baseline, after 4 weeks using device, after 8 weeks using device
Secondary GI (Gastrointestinal) Pain Intensity A secondary outcome will be a decrease in PROMIS (Patient Reported Outcomes Measurement Information System) GI Pain scores scored on a scale of 1-5 with 1 being low pain intensity and 5 being high. These scores are summed for a raw score, which may be converted into a T-score. Baseline, after 4 weeks using device, after 8 weeks using device
Secondary IBS symptom severity A secondary outcome will be a decrease in patient reported IBS Symptom Severity Score (IBS-SSS).
Scored on a 0-500 scale.
< 75 points - IBS considered in remission
75-174 - mild IBS
175-299 - moderate IBS
300-500 - severe IBS
5 measures
# of days with abdominal pain x 10 - maximum score of 100
1-100 scale for abdominal pain severity
0-100 scale for abdominal distension severity
0-100 scale for satisfaction with bowel habits
0-100 scale for interference with life'
Weekly for 8 weeks
Secondary Visceral anxiety A secondary outcome will be a decrease in patient reported Visceral Sensitivity Index (VSI) scores.
Each question is positively scored 1-6. 1 represents the most visceral anxiety and 6 represents no visceral anxiety.
The VSI items then are reversed scored, meaning that the 1-6 becomes 5-0. These reverse scores are then summed. The max score, representing severe visceral anxiety is 75. The minimum score is 0 (no visceral anxiety).
Baseline, after 4 weeks using device, after 8 weeks using device
Secondary Generalized anxiety A secondary outcome will be a decrease in PROMIS (Patient Reported Outcomes Measurement Information System) Anxiety scores. Each question is positively scored 1-5 (meaning that 1 is no anxiety and 5 the highest anxiety), then summed for raw score, which may be converted into a T-Score. Baseline, after 4 weeks using device, after 8 weeks using device
Secondary Maladaptive GI (Gastrointestinal) cognitions A secondary outcome will be a decrease in patient reported Gastrointestinal Cognitions Questionnaire (GI-COG) scores.
Each question is scored positively from 0-4, then summed for raw score. Raw scores 0-19, 20-39, and 40-64 indicate mild catastrophizing, moderate catastrophizing, and severe catastrophizing respectively.
Baseline, after 4 weeks using device, after 8 weeks using device
Secondary Somatization A secondary outcome will be a decrease in patient reported Patient Health Questionnaire (PHQ-15) scores.
Each question is positively scored 0-2, then summed for raw score. The total PHQ-15 score ranges from 0 to 30 and scores of =5, =10, =15 represent mild, moderate and severe levels of somatization, respectively.
Baseline, after 4 weeks using device, after 8 weeks using device
Secondary Increase in Symptom Relief A secondary outcome will be an increase in patient reported "Adequate Relief" global assessment. This is a binary outcome (yes or no) End of Study, which will occur after 8 weeks using device
Secondary Optional Individual Cognitive Interviews Obtaining qualitative feedback from participants in the treatment group about their experiences with the SynerGI software End of Study, which will occur after 8 weeks using device
Secondary Optional Rome IV Criteria assessment Using the fourth version of the Rome Criteria, potential participants may self-diagnose themselves with IBS. At screening/baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT06297785 - Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS) N/A
Recruiting NCT05874830 - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A
Completed NCT05565612 - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Completed NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Recruiting NCT06215222 - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Completed NCT06426745 - Split-dose Versus Single-dose Bowel Preparation for Colonoscopy N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Recruiting NCT05990764 - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS) N/A
Completed NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A